INCYTE CORP (INCY) earnings date
Feb 9, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 52% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 29 days, typically, give or take 6 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Oct 29, 2026 | before open | 29 | 8-K |
| Q2 FY2026 | Tue, Jul 28, 2026 | before open | 28 | 8-K |
| Q1 FY2026 | Tue, Apr 28, 2026 | before open | 28 | 8-K |
| Q4 FY2025 | Tue, Feb 10, 2026 | before open | 41 | 8-K |
| Q3 FY2025 | Tue, Oct 28, 2025 | before open | 28 | 8-K |
| Q2 FY2025 | Tue, Jul 29, 2025 | before open | 29 | 8-K |
| Q1 FY2025 | Tue, Apr 29, 2025 | before open | 29 | 8-K |
| Q4 FY2024 | Mon, Feb 10, 2025 | before open | 41 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 FOR IMMEDIATE RELEASE Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates Total revenue of $1.56 billion and total net sales of $1.32 billion in the third quarter of 2026, each an increase of 14% compared to the third quarter of 2025 Jakafi ® /Jakafi XR ™ (ruxolitinib) net sales of $827 million, an increase of 4% compared to the same period in 2025 Continued growth in core business (ex-Jakafi), with Opzelura ® (ruxolitinib) cream net sales of $255 million and Hematology and Oncology net sales of $235 million, an increase of 36% and 38%, respe" exhibit |
| Q3 FY2026 | "Cash, cash equivalents and marketable securities position: As of September 30, 2026 and December 31, 2025, cash, cash equivalents and marketable securities totaled $3.9 billion and $3.6 billion, respectively. 2026 Financial Guidance Incyte is raising its full year 2026 net sales guidance for Opzelura to $1,100 - $1,120 million, Hematology and Oncology to $890 - $910 million and total net sales to $5,210 - $5,300 million to reflect continued strong performance across the portfolio." exhibit |
| Q3 FY2026 | "Incyte is reaffirming its full year 2026 guidance for all other categories." exhibit |
| Q3 FY2026 | "Incyte’s guidance for the fiscal year 2026 is summarized below." exhibit |
| Q3 FY2026 | "A Phase 3 study (EXCALIBUR-MF2) is expected to initiate by year end 2026, following positive End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA) in the third quarter." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 FOR IMMEDIATE RELEASE Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates Total revenue of $1.67 billion and total net sales of $1.49 billion in the second quarter of 2026, an increase of 38% and 40%, respectively, compared to the second quarter of 2025 Total net sales, excluding the one-time, non-cash benefit for Opzelura ® (ruxolitinib) cream related to the CMS settlement, * grew 17% compared to the prior year period Jakafi ® /Jakafi XR ™ (ruxolitinib) net sales of $817 million, an increase of 7% compared to the same period in 2025 Opzelu" exhibit |
| Q2 FY2026 | "With ten data readouts expected in the second half of 2026, alongside product launches through early next year, we are well positioned for our next phase of growth.”" exhibit |
| Q2 FY2026 | "Opzelura Net Sales 1 Total estimated incremental impact on Opzelura net sales for the full year 2026 $300 - $310 million One-time, non-cash benefit of the reversal of previously established accrued balances through the first quarter of 2026 ending March 31, 2026 $246 million Impact on second quarter of 2026 net sales resulting in improved GTN $15 million Estimated impact on third and fourth quarters of 2026 net sales from improved GTN $40 - $50 million 1 Totals may not add due to rounding. 2026 Financial Guidance Incyte is raising its full year 2026 total net sales guidance to $5,130 - $5,260 " exhibit |
| Q2 FY2026 | "Incyte is raising its full year 2026 Opzelura net sales guidance to $1,050 - $1,100 million and full year 2026 Hematology and Oncology net sales guidance to $860 - $890 million." exhibit |
| Q2 FY2026 | "Incyte is also raising its full year 2026 operating expense guidance." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/INCY
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/INCY
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/INCY/"><img src="https://veritasdata.dev/embed/INCY.svg" alt="INCY earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/INCY/)
Script
<script async src="https://veritasdata.dev/embed/INCY.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/INCY"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.